Short Interest in Cocrystal Pharma, Inc. (NASDAQ:COCP) Drops By 94.5%

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the target of a large drop in short interest in the month of October. As of October 31st, there was short interest totalling 2,000 shares, a drop of 94.5% from the October 15th total of 36,200 shares. Based on an average daily volume of 17,600 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are short sold.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price target on shares of Cocrystal Pharma from $10.00 to $7.00 and set a “buy” rating on the stock in a research note on Thursday, August 22nd.

Cocrystal Pharma Stock Performance

Shares of NASDAQ:COCP traded up $0.01 on Tuesday, reaching $1.76. The company’s stock had a trading volume of 11,652 shares, compared to its average volume of 20,845. Cocrystal Pharma has a 52-week low of $1.33 and a 52-week high of $3.10. The company has a 50-day simple moving average of $1.80 and a 200 day simple moving average of $1.99. The company has a market cap of $17.90 million, a P/E ratio of -0.99 and a beta of 1.45.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings results on Wednesday, August 14th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.02). On average, equities research analysts forecast that Cocrystal Pharma will post -1.94 EPS for the current fiscal year.

Cocrystal Pharma Company Profile

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.